Outlook Therapeutics Inc. (OTLK)
NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OTLK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $94.94M
- EPS (TTM)
- -$0.70
- Dividend yield
- None
- 52-week range
- 0.161 – 2.54
- Day range
- 0.36 – 0.40
- Volume / Avg
- 5.18M / 4.60M
- Beta
- —
- Shares outstanding
- 243.45M
- Next earnings
- Dec 18, 2026
52-week range
OTLK stock today
Outlook Therapeutics (OTLK) closed at $0.39 on Nov 20, down 2.74% (-$0.011), versus the S&P 500's 3.70% decline. At this level, OTLK sits near the bottom of its 52-week range of $0.161 to $2.54: 84.6% below the high, set on Dec 17, 2025 and 142.2% above the low. OTLK is down 75.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 79.3%.
Outlook Therapeutics has posted a net loss over the last twelve months (EPS of -$0.70), so its P/E ratio is not meaningful. Outlook Therapeutics's next earnings report is expected on Dec 18, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Outlook Therapeutics
Company profileOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Robert Charles Jahr
- Headquarters
- Iselin, NJ
- Employees
- 17
- IPO year
- 2016
- Website
- outlooktherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Outlook Therapeutics generated $1.4 million in revenue. Outlook Therapeutics reported a net loss of $62.4 million, compared with a loss of $75.4 million a year earlier. Gross margin was 4.0% and operating margin -4744.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.41M | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-62.42M | $-75.37M | $-58.98M | $-66.05M | $-53.16M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.72 | $-0.31 | $-0.35 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$5.03+1189.74%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 18, 2026
- EPS estimate
- $-0.08
- Last reported (Q3 2026)
- Aug 12, 2026
- EPS actual vs est.
- $-0.15 vs —
OTLK news
All OTLK newsOutlook Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VYGRVoyager Therapeutics Inc. | 1.53 | -4.97% | $95.21M | vs OTLK |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs OTLK |
| LENZLENZ Therapeutics Inc. | 2.97 | -11.23% | $93.16M | vs OTLK |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs OTLK |
| ZURAZura Bio Limited Class A | 0.9305 | -2.30% | $89.63M | vs OTLK |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs OTLK |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs OTLK |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs OTLK |
Indexes, lists and sector
Outlook Therapeutics stock FAQ
What is Outlook Therapeutics's stock price today?
OTLK last traded at $0.39 as of Nov 20, 4:00 PM EST, down 2.74% on the day. Prices are delayed at least 15 minutes.
Does Outlook Therapeutics pay a dividend?
No. Outlook Therapeutics does not currently pay a regular cash dividend.
When is Outlook Therapeutics's next earnings date?
Outlook Therapeutics is expected to report earnings on Friday, December 18, 2026. Analysts expect EPS of $-0.08.
Who is Outlook Therapeutics's CEO?
Mr. Robert Charles Jahr is the chief executive officer of Outlook Therapeutics Inc., which has about 17 employees.
Has OTLK ever split its stock?
Yes. The most recent OTLK stock split was a 1-for-20 split on Mar 14, 2024, one of 2 splits on record.
What is the OTLK 52-week high?
The 52-week high for OTLK is $2.54 and the 52-week low is $0.161. The stock is currently 84.6% below its high.